The study aims to explore how type 2 diabetes mellitus (T2DM) affects platelet function, specifically focusing on the immature platelet fraction (IPF) and other platelet indices. The research was conducted at Guru Teg Bahadur Hospital in New Delhi, India, and involved 230 participants, equally divided between T2DM patients and healthy controls.
The article discusses the potential use of targeted-release budesonide (TRF-budesonide) in treating IgA nephropathy (IgAN), a common kidney disease characterized by IgA deposits in the kidneys. IgAN can lead to end-stage renal disease, and current treatments like ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) aren’t always effective in slowing disease progression.
The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.
The American Association of Clinical Endocrinology (AACE) has introduced a new guideline for managing dyslipidemia, which refers to abnormal cholesterol levels. This guideline provides evidence-based recommendations for newer drug therapies and emphasizes patient-centered outcomes, particularly the reduction of cardiovascular disease (CVD) risk. It is intended for adults aged 18 and older who have dyslipidemia or high triglycerides and are already receiving standard treatment but may need additional medications.
The U.S. Food and Drug Administration (FDA) has given the green light to a new combination therapy for adults suffering from specific types of relapsed or hard-to-treat large B-cell lymphomas (LBCL) who are not suitable candidates for stem cell transplants or CAR-T therapy. This innovative treatment consists of brentuximab vedotin (Adcetris), lenalidomide, and rituximab (BV+R2). It specifically targets types of LBCL such as diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL that arises from slower-growing lymphoma.
